Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionWorldquant Millennium Advisors Llc
Latest Disclosed Ownership42,160 shares
Latest Disclosed Value $ 13,949,479
Worldquant Millennium Advisors Llc reports 87.72% decrease in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 15, 2026 - Worldquant Millennium Advisors Llc filed a 13F-HR form disclosing ownership of 42,160 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $12,045,112 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 343,431 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of -87.72% during the quarter. The current value of the position is $10,982,680 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 42,160 -301,271 -87.72 13,949 -89.79 0.0538
2026-02-17 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 343,431 122,797 55.66 136,565 35.74 0.5298
2025-11-14 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 220,634 103,261 87.98 100,609 162.87 0.4346
2025-08-14 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 117,373 -73,732 -38.58 38,274 -25.83 0.1901
2025-05-15 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 191,105 40,914 27.24 51,602 46.01 0.3252
2025-02-14 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 150,191 91,671 156.65 35,341 119.59 0.2289
2024-11-14 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 58,520 -71,073 -54.84 16,095 -48.89 0.1178
2024-08-14 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 129,593 69,520 115.73 31,491 250.80 0.2872
2024-05-15 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 60,073 -894 -1.47 8,978 -23.07 0.1108
2024-02-14 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 60,967 60,967 11,670 0.1633
2023-11-14 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -40,287 -100.00 0 -100.00
2023-08-14 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 40,287 21,949 119.69 7,652 254,966.67 0.1295
2023-05-15 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 18,338 18,338 4 0.0680
2023-02-14 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -20,426 -100.00 0 -100.00
2022-11-14 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 20,426 20,426 4,088 0.0993
2021-11-15 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -31,999 -100.00 0 -100.00
2021-08-16 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 31,999 3,271 11.39 5,424 33.73 0.1199
2021-05-17 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 28,728 0 0.00 4,056 8.62 0.0861
2021-02-16 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 28,728 0 0.00 3,734 -10.73 0.0816
2020-11-16 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 28,728 -13,951 -32.69 4,183 -33.82 0.0991
2020-08-14 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 42,679 6,533 18.07 6,321 60.68 0.1455
2020-05-14 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 36,146 23,424 184.12 3,934 168.53 0.0957
2020-02-14 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,722 12,722 1,465 0.0280
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.